Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world. Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are known to be a major driver of PDAC progression, but it was considered an undru...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillson, Josef, Ramaswamy, Yogambha, Singh, Gurvinder, Gorfe, Alemayehu A., Pavlakis, Nick, Samra, Jaswinder, Mittal, Anubhav, Sahni, Sumit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281596/
https://www.ncbi.nlm.nih.gov/pubmed/32456277
http://dx.doi.org/10.3390/cancers12051341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281596/
https://www.ncbi.nlm.nih.gov/pubmed/32456277
http://dx.doi.org/10.3390/cancers12051341

Ejemplares similares